View in EDS HTML Full Text PDF Full Text

A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland.

Saved in:
Bibliographic Details
Title: A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland.
Authors: Besson J; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland. Juliette.Besson@hotmail.com., Audran R; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland., Karlen M; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Miauton A; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Hajjami HM; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland., Warpelin-Decrausaz L; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.; Research Support Unit, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Sene L; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland., Schaufelberger S; Information Systems and Digital Transformation, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Faivre V; Information Systems and Digital Transformation, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Faouzi M; Division of Biostatistics, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Hartley MA; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Spertini F; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland., Genton B; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Source: BMC infectious diseases [BMC Infect Dis] 2025 Apr 07; Vol. 25 (1), pp. 472. Date of Electronic Publication: 2025 Apr 07.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40197245
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Besson+J%22">Besson J</searchLink>; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland. Juliette.Besson@hotmail.com.<br /><searchLink fieldCode="AU" term="%22Audran+R%22">Audran R</searchLink>; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Karlen+M%22">Karlen M</searchLink>; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Miauton+A%22">Miauton A</searchLink>; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Hajjami+HM%22">Hajjami HM</searchLink>; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Warpelin-Decrausaz+L%22">Warpelin-Decrausaz L</searchLink>; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.; Research Support Unit, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Sene+L%22">Sene L</searchLink>; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Schaufelberger+S%22">Schaufelberger S</searchLink>; Information Systems and Digital Transformation, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Faivre+V%22">Faivre V</searchLink>; Information Systems and Digital Transformation, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Faouzi+M%22">Faouzi M</searchLink>; Division of Biostatistics, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Hartley+MA%22">Hartley MA</searchLink>; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Spertini+F%22">Spertini F</searchLink>; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Genton+B%22">Genton B</searchLink>; Tropical, Travel and Vaccination Clinic, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100968551%22">BMC infectious diseases</searchLink> [BMC Infect Dis] 2025 Apr 07; Vol. 25 (1), pp. 472. <i>Date of Electronic Publication: </i>2025 Apr 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100968551 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1471-2334 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214712334%22">14712334 </searchLink><i>NLM ISO Abbreviation: </i>BMC Infect Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40197245
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12879-025-10844-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 472
    Titles:
      – TitleFull: A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Besson J
      – PersonEntity:
          Name:
            NameFull: Audran R
      – PersonEntity:
          Name:
            NameFull: Karlen M
      – PersonEntity:
          Name:
            NameFull: Miauton A
      – PersonEntity:
          Name:
            NameFull: Hajjami HM
      – PersonEntity:
          Name:
            NameFull: Warpelin-Decrausaz L
      – PersonEntity:
          Name:
            NameFull: Sene L
      – PersonEntity:
          Name:
            NameFull: Schaufelberger S
      – PersonEntity:
          Name:
            NameFull: Faivre V
      – PersonEntity:
          Name:
            NameFull: Faouzi M
      – PersonEntity:
          Name:
            NameFull: Hartley MA
      – PersonEntity:
          Name:
            NameFull: Spertini F
      – PersonEntity:
          Name:
            NameFull: Genton B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 04
              Text: 2025 Apr 07
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1471-2334
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: BMC infectious diseases
              Type: main
ResultId 1